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Abstract
Clinical trials have shown that strong tumor antigen–specific
CD8 T-cell responses are difficult to induce but can be achieved
for T-cells specific formelanoma differentiation antigens, upon
repetitive vaccination with stable emulsions prepared with
synthetic peptides and incomplete Freund’s adjuvant. Here, we
show in four melanoma patients that ex vivo detectable T-cells
and thus strong T-cell responses can also be induced against
the more universal cancer-testis antigens NY-ESO-1 and Mage-
A10. Interestingly, all patients had ex vivo detectable T-cell
responses against multiple antigens after serial vaccinations
with three peptides emulsified in incomplete Freund’s adju-
vant. Antigen-specific T-cells displayed an activated phenotype
and secreted IFN;. The robust immune responses provide a
solid basis for further development of human T-cell vaccina-
tion. (Cancer Res 2006; 66(4): 1912-6)
Introduction
Amajor goal in the development of active immunotherapy against
cancer is the strong activation of self/tumor antigen–specific CD8
T-cells. For protection against disease, it is likely that frequencies
of antigen-specific T-cells need to reach at least 0.01% to 1% of
circulating CD8 T-cells and thus become detectable ex vivo , as is the
case for antiviral CD8 T-cell responses (1–3). To protect from long-
term disease, the (relatively) high levels of activated T-cells must
be maintained and/or boosted over an extended period of time.
Therefore, therapeutic vaccination should repetitively induce
ex vivo detectable T-cell responses. It is not sufficient to show
T-cell responses only after in vitro T-cell expansion through
cultivation for several days to weeks because this only shows
that T-cells can be (re-)activated in vitro upon stimulation, leaving
the questions on eventual ongoing in vivo activity largely open.
For optimization of immunotherapy, it is necessary to compare
the various candidate vaccines with respect to their capacity
to activate CD8 T-cells. Unfortunately, methods and techniques
applied to measure antigen-specific CD8 T-cells vary enormously,
making it difficult to oversee the strengths and weaknesses of
numerous novel vaccination approaches (4–10). For a more
rational evaluation of vaccine efficacy, we apply a standardized
and reproducible procedure measuring human antigen-specific
CD8 T-cells ex vivo (11). Through comparison of different adjuvants
for peptide vaccination of melanoma patients, we found that stable
emulsions with incomplete Freund’s adjuvant are powerful to
induce ex vivo detectable and thus strong activation of antigen-
specific T-cells in f50% of patients (12).
The primary goal of our present study was to achieve activation of
T-cells specific for cancer-testis (CT) antigens, such as NY-ESO-1 and
Mage-A10. In contrast to T-cells specific for melanocyte differenti-
ation antigens (Melan-A/Mart-1, gp100, and tyrosinase), no clinical
study with synthetic vaccines has yet reported ex vivo detectable CT
antigen-specific T-cell responses despite the development of many
new cancer vaccines (4–10). CTantigens are expressed in a variety of
tumors, including melanoma, breast, ovarian, and lung cancers and
sarcomas, with increasing expression in advanced-stage disease (13).
Thus, CT-based immunotherapy is potentially applicable in large
numbers of patients provided that it can be optimized to achieve
clinical benefit.
In this study, we aimed to elicit T-cell responses against multiple
antigens by vaccination with a formulation containing three
different peptides (two CT antigens + one differentiation antigen)
mixed together in one single emulsion. Here, we show that this
approach induced ex vivo detectable CT antigen-specific T-cell
responses against multiple epitopes.
Patients and Methods
Patients and study protocol. HLA-A2+ patients with metastatic skin
melanoma were included after written informed consent in this phase I
prospective trial, approved by the local institutional review boards and the
Ludwig Institute for Cancer Research Protocol Review Committee. Patients
had a Karnofsky performance status of z70%, normal blood cell counts and
kidney-liver function, and no concomitant antitumor therapy or immuno-
suppressive drugs. Tumor antigen expression before study inclusion was
assessed on resected metastases. Expression of NY-ESO-1 and Melan-A was
detected in all patients. Expression of Mage-A10 was detected in two patients
(LAU 50 and 701). Vaccinations were given s.c. in monthly intervals. Vaccines
were composed of 3  500 Ag peptide [NY-ESO-1157-165 SLLMWITQA
analogue (14), Mage-A10254-262 GLYDGMEHL (15), and Melan-A26-35 ELAGI-
GILTVanalogue (16)] and 1mLMontanide ISA-51, prepared altogether in one
syringe as a stable emulsion (2 mL injection volume). Peptides were provided
by ClinAlfa, MerckBiosciences (La¨ufelfingen, Switzerland), and adjuvant
(incomplete Freund’s adjuvant; Montanide ISA-51) was provided by Seppic
(Paris, France). Patient LAU 940 received four vaccinations; the other three
patients received 12 vaccinations.
Flow cytometry. Ficoll-Paque centrifuged peripheral blood mononuclear
cells (PBMC; 107) were cryopreserved in RPMI 1640, 40% FCS, and 10%
DMSO. Phycoerythrin-labeled HLA-A*0201/peptide multimers (originally
called tetramers) were prepared as described (12). Five color stains were
done with HLA-A2/peptide multimers, anti-CD28FITC, anti-CD45RAECD,
anti-CD8APC-Cy7 reagents, and anti-CCR7 monoclonal antibody (mAb)
followed by goat anti-rat IgGAPC mAb. Cells (106) were incubated with
multimers (1 Ag/mL, 60 minutes, room temperature) and then with mAbs
(30 minutes, 4jC). CD8+ T-cells (5  105) per sample were acquired with a
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FACSVantage SE machine and data were analyzed with CellQuest software
(BD Biosciences, San Jose, CA).
Functional assays. Multimer+ CD8+ T-cells were ex vivo sorted by flow
cytometry and cloned as described (12). Antigen-specific lysis was assessed
in 4-hour 51Cr release assays (12). IFNg Elispot assay plates were done by
incubating untreated PBMCs for 18 hours at 37jC with and without
peptides, including HIV-1 polymerase peptide ILKEPVHGV as negative
control. Results of both multimer+ T-cells and Elispot-forming T-cells were
calculated and are indicated in percentage of CD8+ T-cells.
Results and Discussion
Frequent and strong ex vivo detectable responses of CD8
T-cells specific for NY-ESO-1, Mage-A10, and Melan-A/Mart-1.
Patients received repetitive monthly vaccinations with the three
synthetic peptides emulsified in incomplete Freund’s adjuvant.
PBMCs collected before and after vaccination were analyzed
ex vivo by flow cytometry using CD8-specific mAb and HLA-A2/
peptide multimers (Fig. 1A) in a validated immune-monitoring
approach identifying real frequency changes of circulating T-cells
(11). All four patients of this study exhibited increased percentages
of antigen-specific CD8+ T-cells reaching ex vivo detectable levels
(0.03-8.9%), and thus had much higher frequencies of CT antigen-
specific T-cells compared with previous reports (4–6). Analysis over
time revealed that, already after 4 monthly vaccinations, increased
frequencies were found in four of four patients for NY-ESO-1-
specific T-cells, in two of four patients for Mage-A10, and in three
of four patients for Melan-A-specific T-cells (Fig. 1B). Therefore,
T-cell responses developed more rapidly than in the majority of
published cancer vaccine studies (7, 8). For Mage-A10, two of four
patients remained initially negative, but nevertheless became
strong responders after eight vaccinations. The present results
show for the first time in humans that vaccination with peptide in
Figure 1. Ex vivo detectable T-cell
responses specific for NY-ESO-1,
Mage-A10, and Melan-A/Mart-1. After
vaccination, PBMCs were collected and
analyzed ex vivo by flow cytometry with
fluorescent peptide/HLA-A*0201 multimers
and CD8-specific mAb. A, numbers
indicate percentages of NY-ESO-1,
Mage-A10, and Melan-A-specific cells of
total CD8+ T-cells. Data are the highest
reached percentages after vaccination for
each patient and antigen. Dot plots in the
right column, representative examples of
controls: Before vaccination, NY-ESO-1-
specific (ii , patient LAU 957) and
Mage-A10-specific (iii , patient LAU 701)
T-cells were undetectable, similar to HIV
polymerase–specific T-cells after
vaccination (i , patient LAU 50). In contrast,
and as frequently observed (12), Melan-A-
specific T-cells can be detected ex vivo
even before vaccination (iv , patient LAU
940). B, response kinetics of T-cells
specific for NY-ESO-1, Mage-A10, and
Melan-A. Multimer+ T-cells in percent of
circulating CD8+ T-cells (similarly as in A),
demonstrating increased values (11) after
vaccination compared with before, for all
three antigens in all four patients, with the
exception of the nonresponding Melan-A-
specific T-cells of patient LAU 701. Vertical
lines, time points of monthly vaccinations.
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incomplete Freund’s adjuvant, when coadministered in a large
volume of stable emulsion, can frequently elicit ex vivo detectable
CT antigen-specific CD8+ T-cell responses in melanoma patients.
The high values of NY-ESO-1-specific T-cells in patient LAU 50
represent an astonishing rare exception (17). This patient had
strongly increased percentages already before immunotherapy,
with 3.4% of NY-ESO-1-specific T-cells shortly before study
inclusion (Fig. 1B). In >99% of HLA-A2+ individuals, CT antigen-
specific T-cells are not detectable ex vivo (4, 5, 17), as also
confirmed before vaccination for all other patients and for all
Mage-A10-specific T-cells (Fig. 1A and B).
Differentiation to effector memory T-cells. For characteriza-
tion of T-cell differentiation, we assessed the expression of
CD45RA, CCR7, and CD28. These receptors are well expressed on
the cell surface of naı¨ve T-cells and are progressively down-
regulated upon T-cell activation and differentiation to effector and/
or memory cells (18, 19). Ex vivo analysis by multicolor flow
cytometry and gating on multimer+ T-cells revealed that after
vaccination, the majority of antigen-specific T-cells expressed only
low levels of CD45RA and CCR7 (Fig. 2). Thus, the vaccine-induced
T-cells displayed an effector memory phenotype (18). This result is
similar to our previous observation in Melan-A-specific T-cells that
were strongly activated by vaccination of melanoma patients with
peptide, incomplete Freund’s adjuvant, and CpG oligonucleotides
(12). Interestingly, the vast majority of antigen-specific T-cells
remained CD28 positive, which was the case in all patients and
for all T-cell specificities, except for the very strongly activated NY-
ESO-1-specific T-cells of patient LAU 50. To assess T-cell function,
PBMC were analyzed with validated (11) IFNg Elispot assays by
overnight incubation with antigenic peptides. Antigen-specific
IFNg responses were found against NY-ESO-1, Mage-A10, and
Melan-A (Fig. 3A), confirming differentiation to effector cytokine-
secreting cells. Unfortunately, it was not possible to determine
whether T-cells had been CD45RA+ and CCR7+ and thus
presumably naı¨ve before vaccination, because CT antigen-specific
T-cells are rarely detectable ex vivo even in patients with advanced
cancers. Thus, the question remains open whether T-cells had been
primed by vaccination. Alternatively, T-cells may have been primed
by tumor-derived antigen and subsequently boosted by vaccina-
tion, which was the case for NY-ESO-1-specific T-cells from patient
LAU 50 (17).
Cross-reactivity to natural NY-ESO-1 and Melan-A antigens.
For vaccination, we had decided to use NY-ESO-1 and Melan-A
analogue peptides, because these carefully selected analogue
peptides bind more stably to HLA-A*0201 and are more
immunogenic compared with the wild-type peptides (14, 16). It
was important to assess whether the vaccination induced T-cells
were capable to recognize natural antigen. This was indeed the
case because IFNg Elispot assays showed comparable activity
against analogue and natural peptides (Fig. 3B). The data for
Melan-A confirm previous in vitro and in vivo studies showing that
the majority of Melan-A-specific T-cells primed by the analogue
peptide were capable to recognize natural peptides and melanoma
cells (16). To assess killing of tumor cells, we generated 18 NY-ESO-
1-specific clones from postvaccination PBMC of patient LAU 50.
The clones successfully killed autologous Me 275 and allogenic Me
290 melanoma cells (A*0201+/NY-ESO-1+). As expected, NA8-MEL
cells (A*0201+/NY-ESO-1) were not recognized unless exogenous
peptide was added to the cytotoxicity assay (Fig. 3C). Together, the
data show that after vaccination with these analogue peptides,
T-cells are often capable to recognize natural antigens and tumor
cells based on physiologic antigen presentation.
Favorable clinical evolution in three of four patients.
Vaccination caused no major side effects. Minor systemic side
effects were transient and included mild myalgia and fatigue
(two patients). As observed earlier (12), patients developed local
inflammatory signs (induration, erythema, and mild to moderate
pain) at s.c. injection sites (three patients). Interestingly, one
patient (LAU 957) showed local skin depigmentation and
regenerated inflammatory signs at several previous injection sites
after booster injections at distant sites. Three patients had
progressive disease at study entry. Patient LAU 940 developed
further metastases during treatment and died 6 months after study
inclusion. Patient LAU 50 experienced a complete remission with
regression of s.c. lesions as detected by positron emission
tomography scans, lasting 12+ months. Multiple skin metastases
Figure 2. Dominant effector memory
phenotype of tumor antigen-specific
T-cells. Expression of CD45RA, CCR7,
and CD28 is shown for antigen-specific
(multimer+ gated) CD8+ T-cells, and for
comparison of total CD8+ T-cells
(histograms to the right). Results from
PBMC analyzed ex vivo from patient LAU
50 after vaccination. NY-ESO-1-,
Mage-A10-, and Melan-A-specific T-cells
from the three other patients were
predominantly CD45RA, CCR7, and
CD28+ (data not shown). Numbers,
percentages of cells positive for CD45RA,
CCR7, or CD28.
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of patient LAU 701 partially reduced in size between the 2nd and
7th study month, with consecutive surgical resection. Finally,
patient LAU 957 had no evidence of disease at study entry and
remained so (12+ months). However, as phase I studies are not
designed to assess clinical efficacy, it is necessary to perform trials
with larger patient numbers and longer follow-up to obtain
representative data on clinical responses.
In previous studies, T-cell responses to NY-ESO-1 in cancer
patients did not reach frequencies of z0.01% circulating CD8
T-cells (4–6, 10), despite considerable efforts using diverse
vaccine formulations (recombinant viruses, DNA, peptides,
proteins, adjuvants, etc). Several reasons may account for the
improved vaccine efficacy found in the present study: We
administered the two CT peptides together with a differentiation
antigen (the Melan-A peptide), leaving the possibility that
responses to one (differentiation) antigen may have helped T-
cells with specificity to further antigens. Second, we have used
doses of peptides (0.5 mg) and incomplete Freund’s adjuvant
(1 mL), which were slightly increased compared with previous
studies. Third, we have optimized the vaccine formulation with
the goal to maximize emulsion stability. The relative volumes
of the components (incomplete Freund’s adjuvant and PBS/
peptides) were precisely adapted, and the amount of DMSO (0.3
mL) used to solubilize the NY-ESO-1 peptide was kept as low as
possible. The emulsion was prepared with a syringe, resulting in
superior stability as opposed to the frequently applied vortex
method. Consequently, our emulsions remained stable for >1
month of storage at room temperature. Finally, the large volume
of the vaccine (2 mL) may have contributed to the long
persistence in the s.c. tissue, and the strong immunogenicity of
this vaccine formulation.
It is important to elucidate the mechanisms underlying strong
T-cell responses in humans, by evaluating hypotheses of immune
activation implicating natural killer and dendritic cells, CD4 T-cell
help, cytokines, and more. On this road, ex vivo detectable T-cells
are a central benchmark, not only because they represent
reasonably high T-cell frequencies, but also because they allow
direct (i.e., ex vivo) molecular and functional investigation of
antigen-specific T-cells. This is the strategy of choice to avoid the
need for in vitro T-cell expansion, which leads to nonphysiologic
alterations in T-cell repertoire, activation, and differentiation
stage. Currently, we are characterizing large numbers of individual
T-cells and dominant clonal bursts ex vivo , because we believe
that this approach represents an important technical step toward
a better understanding of protective immunity against cancer and
infection (20).
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Figure 3. IFNg secretion, recognition of
natural and analogue peptides, and tumor
cell lysis. A, Elispot assays were done with
PBMC withdrawn before (pre) and
after (post ) vaccination to determine the
percentage of spot-forming cells of CD8+
circulating T-cells specific for NY-ESO-1
analogue, Mage-A10, and Melan-A
analogue peptide. B, IFNg Elispot assays
comparing reactivity to analogue versus
natural peptides (NY-ESO-1 analogue
SLLMWITQA, natural SLLMWITQC;
Melan-A analogue ELAGIGILTV, natural
EAAGIGILTV). C, NY-ESO-1-specific
T-cells from patient LAU 50 were sorted by
flow cytometry and cloned, and cytotoxicity
was tested against melanoma cell lines
Me 275 (NY-ESO-1+), Me 290
(NY-ESO-1+), and NA8-MEL
(NY-ESO-1) in the absence (white
columns ) or presence (black columns ) of
synthetic NY-ESO-1 analogue peptide
(1 Amol/L). Clone 38 was generated from
blood obtained 9 days after the 12th
vaccination, and clone 94 from blood was
obtained 10 days after the 4th vaccination.
Further 11 clones were capable to lyse
tumor cells in the absence of synthetic
peptides, whereas five other clones killed
peptide-loaded but not unloaded tumor
cells (not shown).
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